{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:54:33Z","timestamp":1777859673853,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To summarize the current literature for Food and Drug Administration (FDA)-approved monoclonal antibodies used as add-on maintenance therapy in uncontrolled eosinophilic asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>PubMed was searched on December 17, 2018 using keywords: asthma, eosinophilic asthma, omalizumab, reslizumab, mepolizumab, benralizumab, and dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Studies evaluating safety and efficacy of monoclonal antibodies for treatment of severe or eosinophilic asthma were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one randomized, double-blind, placebo-controlled trials evaluating the current FDA-approved monoclonal antibodies (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) for the treatment of uncontrolled eosinophilic asthma were included. The studies demonstrated clinically significant reductions in asthma exacerbations, symptoms, emergency room visits, eosinophil counts, and improvements in pulmonary function and asthma-related quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Five monoclonal antibodies are available for uncontrolled eosinophilic asthma. Choice depends on patient factors. Future studies should focus on cost-effectiveness of treatment, drug-drug comparisons, and long-term efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190019840597","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T22:50:27Z","timestamp":1556837427000},"page":"513-522","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma"],"prefix":"10.1177","volume":"33","author":[{"given":"Renee R.","family":"Koski","sequence":"first","affiliation":[{"name":"Pharmacy Practice, Ferris State University College of Pharmacy, Marquette, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0756-6827","authenticated-orcid":false,"given":"Kirsten M.","family":"Grzegorczyk","sequence":"additional","affiliation":[{"name":"Walgreens, Big Rapids, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"bibr1-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000251"},{"key":"bibr2-0897190019840597","unstructured":"Centers for Disease Control and Prevention [Internet]. Atlanta, GA: CDC; Asthma. Published 2018. Accessed July 1, 2018. https:\/\/www.cdc.gov\/asthma\/most_recent_data.htm"},{"key":"bibr3-0897190019840597","unstructured":"National Institutes of Health [Internet]. Bethesda, MD: NIH; Guidelines for the diagnosis and management of asthma: summary report. Published 2007. Accessed July 1, 2018. https:\/\/www.nhlbi.nih.gov\/health-pro\/guidelines\/current\/asthma-guidelines"},{"key":"bibr4-0897190019840597","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. Published 2018. Accessed December 17, 2018. https:\/\/ginasthma.org\/2018-gina-report-global-strategy-for-asthma-management-and-prevention\/"},{"key":"bibr5-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2017.1322611"},{"key":"bibr6-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.01.013"},{"key":"bibr7-0897190019840597","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S94164"},{"key":"bibr8-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.026"},{"key":"bibr9-0897190019840597","unstructured":"Xolair [package insert]. East Hanover, NJ: Novartis; 2017."},{"key":"bibr10-0897190019840597","unstructured":"Nucala [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017."},{"key":"bibr11-0897190019840597","unstructured":"Cinqair [package insert]. Frazer, PA: Teva; 2016."},{"key":"bibr12-0897190019840597","unstructured":"Fasenra [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017."},{"key":"bibr13-0897190019840597","unstructured":"Dupixent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals and Bridgewater, NJ: Sanofi-Aventis; 2018."},{"key":"bibr14-0897190019840597","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S49409"},{"key":"bibr15-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.117880"},{"key":"bibr16-0897190019840597","unstructured":"European Medicines Agency. [Internet]. London, England: EMA; c1995. http:\/\/www.ema.europa.eu\/ema\/. Accessed December 17, 2018."},{"key":"bibr17-0897190019840597","unstructured":"Average Wholesale Prices. Found at Lexicomp Online\n                      TM\n                      [Internet]. Hudson, OH: Lexicomp. c1978. Accessed December 17, 2018."},{"key":"bibr18-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1177\/2040622316659863"},{"key":"bibr19-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0513-8"},{"key":"bibr20-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.018"},{"key":"bibr21-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1177\/1753465817717134"},{"key":"bibr22-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"bibr23-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"bibr24-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00772.x"},{"key":"bibr25-0897190019840597","unstructured":"ClinicalTrials.gov [Internet]. Bethesda, MD: U.S. National Library of Medicine; c1993. Accessed March 4, 2018. https:\/\/clinicaltrials.gov\/ct2\/home"},{"key":"bibr26-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"bibr27-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"bibr28-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"bibr29-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"bibr30-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"bibr31-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"bibr32-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.010"},{"key":"bibr33-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0396OC"},{"key":"bibr34-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.032"},{"key":"bibr35-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00042-9"},{"key":"bibr36-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30190-X"},{"key":"bibr37-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.01.003"},{"key":"bibr38-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703501"},{"key":"bibr39-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"bibr40-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"bibr41-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"bibr42-0897190019840597","unstructured":"Business Wire: Teva announces top-line results from Phase III studies of subcutaneously administered reslizumab in patients with severe eosinophilic asthma. [Internet]. New York, NY: Business Wire; c2018. Updated March 19, 2018; Accessed July 12, 2018. https:\/\/www.businesswire.com\/news\/home\/20180122005789\/en\/"},{"key":"bibr43-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201707-1323OC"},{"key":"bibr44-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.10.028"},{"key":"bibr45-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1298444"},{"key":"bibr46-0897190019840597","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.055"},{"key":"bibr47-0897190019840597","unstructured":"AstraZeneca: AstraZeneca provides update on tralokinumab phase III programme in severe, uncontrolled asthma. [Internet]. Global ed. Cambridge, GB: AstraZeneca; c2017. Updated November 1, 2017. Accessed December 15, 2018. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2017\/astrazeneca-provides-update-on-tralokinumab-phase-iii-programme-in-severe-uncontrolled-asthma-01112017.html"},{"key":"bibr48-0897190019840597","doi-asserted-by":"crossref","unstructured":"Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomized, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781\u2013796.","DOI":"10.1016\/S2213-2600(16)30265-X"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190019840597","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190019840597","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190019840597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:35:27Z","timestamp":1777509327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190019840597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1177\/0897190019840597"],"URL":"https:\/\/doi.org\/10.1177\/0897190019840597","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]}}}